VRNA — Verona Pharma Cashflow Statement
0.000.00%
Last trade - 00:00
- $1.28bn
- $1.06bn
- 52
- 25
- 42
- 34
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -40.6 | -65.1 | -55.6 | -68.7 | -54.4 |
Depreciation | |||||
Non-Cash Items | 1.45 | 21.6 | 23.2 | 18.9 | 17.4 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -4.27 | -2.11 | -1.56 | -10.7 | -13.9 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Taxes Payable | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -42.9 | -45.1 | -33.3 | -59.9 | -50.2 |
Capital Expenditures | -0.053 | -0.082 | -0.012 | -0.029 | 0 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 47.4 | 9.79 | 0 | — | — |
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | 47.3 | 9.71 | -0.012 | -0.029 | 0 |
Financing Cash Flow Items | 0 | -12.9 | -6.85 | -15.4 | 52.2 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 0 | 192 | -6.12 | 141 | 92.9 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 5.18 | 158 | -39.6 | 79.4 | 43.9 |